Tofacitinib label tightens focus on infection, clotting, and cardiovascular harm
The updated medication guide for tofacitinib extended-release tablets places the drug’s safety profile front and center. The oral JAK inhibitor remains an option for adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderately to severely active ulcerative colitis when at least one TNF blocker has failed or was not tolerated. But the labeling language is dominated by serious adverse outcomes that demand active screening, ongoing laboratory surveillance, and careful patient selection.
One sentence in the guide carries the weight of the entire risk discussion: this is not a drug for casual initiation in patients with uncontrolled infection risk, vascular disease, or prior malignancy concerns.
Serious infections and the need for pre-treatment screening
Tofacitinib suppresses immune signaling through Janus kinase inhibition, which helps calm inflammatory arthritis and colitis but also weakens the body’s ability to contain pathogens. The label warns of serious infections, including tuberculosis, bacterial sepsis, fungal disease, and viral reactivation. Some infections have been fatal. Before treatment begins, patients need testing for TB, and TB surveillance continues during therapy. Those with active infection should not start treatment unless a clinician decides the infection is controlled.
The infection warning is broader than TB alone. Patients with diabetes, chronic lung disease, HIV, recurrent infections, or a weakened immune system face higher risk. Geographic exposure matters as well: residence in or travel through areas where histoplasmosis, coccidioidomycosis, or blastomycosis are common can materially raise the chance of invasive fungal disease once immune defenses are blunted. Hepatitis B and C history also matters because viral activation can occur during therapy.
Shingles deserves special attention. The guide states that people with ulcerative colitis taking the higher dose of XELJANZ or tofacitinib extended-release tablets carry a higher risk of serious infection and herpes zoster. In practice, that means a clinician has to think beyond joint or bowel symptom control and ask whether the immune system can tolerate the tradeoff.
Cardiovascular events, death, and thrombosis move from theoretical concern to boxed warning reality
The cardiovascular warning is not framed as a remote possibility. In people 50 years of age and older who have at least one cardiovascular risk factor, tofacitinib has been associated with increased risk of death, major cardiovascular events such as heart attack or stroke, and blood clots. The label specifies heightened concern in current or former smokers.
Blood clots have occurred in the lungs, deep veins of the legs or arms, and arteries. Pulmonary embolism, deep vein thrombosis, and arterial thrombosis have all been reported more often in the same higher-risk population. Some patients have died from these events. In ulcerative colitis, blood clots in the lungs have also been observed. The bedside implication is direct: new shortness of breath, chest pain, unilateral limb swelling, leg tenderness, or discoloration during treatment should trigger urgent evaluation and immediate drug interruption.
The pathophysiology fits the warning. JAK inhibition can reduce inflammatory burden, but it may also shift immune and vascular signaling in ways that alter thrombotic and atherosclerotic risk. For older patients already carrying hypertension, smoking history, diabetes, prior vascular disease, or other cardiovascular hazards, the margin for error narrows quickly.
Malignancy and immune surveillance remain a central concern
The medication guide also warns that tofacitinib may increase the risk of certain cancers by changing the way the immune system works. Lymphoma, skin cancers, and lung cancer appear in the warning language, with particularly elevated risk described among current or past smokers. Patients with ulcerative colitis taking the higher dose are also described as having a higher risk of skin cancers.
This matters because immune surveillance is one of the body’s quiet defenses against malignant transformation. When that surveillance is dampened, cancers that might otherwise remain contained can emerge or progress. Patients with a prior cancer history deserve explicit discussion before treatment begins, and dermatologic vigilance should not be an afterthought during longer-term use.
GI perforation, liver disease, and laboratory monitoring shape day-to-day prescribing
The label adds another clinically important hazard: tears, or perforation, in the stomach or intestines. Risk appears higher in people with diverticulitis or ulcers and in those also taking NSAIDs, corticosteroids, or methotrexate. Fever paired with persistent abdominal pain and a change in bowel habits should prompt urgent assessment. In inflammatory bowel disease, where abdominal pain can be easy to attribute to the underlying disorder, this warning has real bedside consequence.
Routine laboratory follow-up is not optional. Blood counts should be checked before treatment and during therapy to monitor lymphocytes, neutrophils, and red blood cells. Low counts may require stopping treatment temporarily, and the drug should not be used if those values are too low. Liver tests also need surveillance because elevated results can make treatment inappropriate. Cholesterol monitoring follows as well, with testing recommended 4 to 8 weeks after starting therapy and as needed thereafter.
The lab abnormalities are not just numbers on a chart. Lymphopenia and neutropenia weaken host defense, anemia can drive fatigue and functional decline, and lipid changes can compound cardiovascular risk in the very population already warned about heart attack and stroke.
Dosing, drug interactions, and special populations require precision
Tofacitinib extended-release tablets are taken once daily, swallowed whole, and not crushed, split, or chewed. Patients may notice an empty tablet shell in stool after the active drug has been absorbed. For psoriatic arthritis, the medication is used with methotrexate, sulfasalazine, or leflunomide as directed.
The label is explicit about combinations to avoid. Concomitant use with other biologic or immunosuppressive therapies such as adalimumab, infliximab, etanercept, abatacept, rituximab, ustekinumab, secukinumab, vedolizumab, ixekizumab, azathioprine, cyclosporine, and several others can intensify infection risk and is not advised. Live vaccines should also be avoided during therapy, while non-live vaccines remain acceptable.
Pregnancy and breastfeeding are handled cautiously. The guide states that the drug may affect the ability of females to get pregnant, and it is not known whether the drug harms an unborn baby. Breastfeeding requires a choice between treatment and nursing; both should not occur together, and breastfeeding should not resume until 36 hours after the last dose.
What the label means for prescribers
Tofacitinib remains a useful anti-inflammatory therapy, but the labeling language makes clear that benefit comes with a narrow safety corridor. Prescribers must weigh disease control against infection risk, thrombotic complications, malignancy concerns, GI perforation, and laboratory toxicity before writing the first prescription. In older adults with cardiovascular risk factors, smokers, and patients with prior cancer, the warning burden becomes especially hard to ignore.
The guide does not leave much ambiguity about how to proceed: screen before starting, monitor during treatment, and stop quickly when serious adverse effects emerge. For a drug that can alter immune and vascular behavior at the same time, that discipline is not administrative overhead. It is the treatment itself.